An interventional study of Visual Stimulation and standard of care in Hemianopsia, Virtual Reality and Visual Rehabilitation, sponsored by Institut National de la Santé Et de la Recherche Médicale, France. Not yet recruiting at 8 sites in 7 countries. Open to participants aged 10 Years to 40 Years. Per ClinicalTrials.gov, last updated 2026-09-16.
Sponsored by Institut National de la Santé Et de la Recherche Médicale, France · Not applicable, Interventional, and Other
Evaluate the efficiency of audiovisual stimulation in virtual reality for improving the visual perception of children, adolescents, and young adults with hemianopia resulting from pediatric brain tumors. These individuals can lose up to 50% of their visual field, significantly impacting their independence, mobility, and daily lives.
63 studies on the registry are indexed under Hemianopsia; 24 are open to participants now.
This study's planned enrollment of 120 is above the median of 32 across 53 interventional studies indexed under Hemianopsia.
Browse Hemianopsia studies →Institut National de la Santé Et de la Recherche Médicale, France is the lead sponsor of 378 studies on the registry; 81 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Standard of care for the first 8 weeks then visual stimulation for the following 8 weeks
Device: Visual Stimulation · Other: standard of care
Visual stimulation for the first 8 weeks then standard of care for the following 8 weeks
Device: Visual Stimulation · Other: standard of care
Our audiovisual stimulation procedure IVR, called 3D-MOT, was encoded using the the 3D Unity programming platform and deployed in HMDs with built-in head/eye tracking. We implemented the multiple object tracking (MOT) paradigm, developed in the 80's to study visual attention in humans, and added correlated spatial sound.
During this phase, the patients will be at home without a headset and will not be exposed to an audio-visual stimulation task in virtual reality.
Visual field perimetry measured using the Esterman binocular field test
Increase at least 3 points in the number of points perceived in the blind field at the Esterman binocular field test after intervention (8 weeks) when compared to baseline and between control and interventional group.
Time frame: From enrollment to the end of follow up period at 6 months
Participant-reported a vision impairment specific quality of life questionnaire: Impact of Vision Impairment Questionnaire (IVI).
Questionnaire will be provided and compared at baseline and after intervention ( 8 weeks) and between control and interventional group. A diminution of the mean score above 0.3-0.5 point will be consider as an amelioration of quality of life impacted by vision impairment.
Time frame: From enrollment to the end of follow up period at 6 months
Reading speed - Minnesota Low Vision Reading (MNREAD) test
Reading speed will be assessed and compared at baseline and after intervention (8 weeks) and between control and interventional groups. An increase in reading speed of 8.6 words per minute on the Minnesota Low Vision Reading (MNREAD) test will be considered an improvement in the variable.
Time frame: From enrollment to the end of follow up period at 6 months
Plan to share: Undecided
No publications or documents are linked to this record.
Start is estimated for Dec 2026; primary completion for Dec 2026, 0 months later.
Of 36 interventional studies with no phase under Hemianopsia, half reached primary completion within 47 months of starting (the median), counting those still running; a quarter within 21 and three quarters within 95. This study's planned 0 months is below that.
How these figures are worked out, and which studies are left out of them.
This study is not yet recruiting, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Institut National de la Santé Et de la Recherche Médicale, France →